ArticleFrontiers in aging neuroscience2025
Quantitative analysis of serum metabolites in a rat model of Alzheimer's disease.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: OXYS rats are a unique animal model of sporadic Alzheimer's disease (AD) that demonstrates all the key signs of AD in humans. Studying metabolic processes in OXYS rats in comparison with control Wistar rats can contribute to understanding the mechanisms of AD development, as well as to establishing metabolomic biomarkers of AD. The main goals of the work are to establish differences in the metabolomic profiles of OXYS and Wistar rat serum at different stages of AD-like pathology (presymptomatic, early and late). Methods: NMR-based metabolomics was applied for metabolomic profiling of blood serum of OXYS and Wistar rats at the age of 20 days (presymptomatic period), 4 months (first manifestation of signs of AD) and 16 months (active development of signs). Results: We determined the concentrations of 55 metabolites present in rat serum. We found that age-related changes in both rat strains reflect animal maturation (20 days to 4 months) and aging (4 months to 16 months), and correspond mainly to amino acid metabolism, purine metabolism, and energy pathways. Potential AD blood biomarkers include lysine, BCAAs, alanine, ornithine, creatine, glutamine and pyruvate. Conclusion: The most significant differences between OXYS and Wistar blood metabolomes were found for 20-day-old animals, which corresponds to the preclinical period of AD development in humans. Metabolomic changes observed in the brain and blood are different and often opposite in sign. Blood serum is potentially promising fluid for AD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.